Sapphiros AiBio
Traditional approaches to R&D in early discovery frequently overlook the nuances of genetic variability among populations and early stage research rarely access true diverse human population cohorts. Our unique biobank asset allow us to understand the complexity of cellular mechanics and function and allows us to model disease in a very unique manner.
There is a significant gap in understanding and addressing the root causes of tissue degeneration and disease particularly in the context of aging populations. As societies age, the prevalence of tissue damage and degenerative diseases like osteoarthritis is on the rise, posing significant challenges to healthcare systems worldwide. Without addressing these issues, the burden of managing age-related ailments will continue to escalate, compromising the quality of life for millions of individuals globally.
Our platform has enabled us to create two interesting programs. One in OA, a second in Parkinson’s disease. We are always looking for partners and collaborators to team with on important therapies.
